Regeneron Pharmaceuticals Inc (REGN)

Interest coverage

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	4,272,300	4,448,500	4,845,000	4,719,500	4,918,200	6,093,600	6,399,300	9,190,200	9,383,100	8,105,000	7,298,800	4,460,200	3,867,300	3,524,400	3,276,100	2,580,200	2,459,300	2,246,400	2,113,400	2,543,700
Interest expense (ttm)	US$ in thousands	73,000	72,100	69,600	63,800	59,400	56,100	55,000	56,300	57,300	58,000	70,100	65,400	56,900	48,800	30,300	28,600	30,200	30,900	30,500	29,400
Interest coverage		58.52	61.70	69.61	73.97	82.80	108.62	116.35	163.24	163.75	139.74	104.12	68.20	67.97	72.22	108.12	90.22	81.43	72.70	69.29	86.52

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $4,272,300K ÷ $73,000K
= 58.52

The interest coverage ratio of Regeneron Pharmaceuticals, Inc. provides insights into the company's ability to cover its interest expenses with its operating income.

Looking at the data provided, the interest coverage ratio for the last four quarters has not been explicitly mentioned for Q4 2023, Q3 2023, Q2 2023, and Q1 2023. However, it is observed that in the previous quarters, the interest coverage ratio was relatively high, with values of 114.81 in Q3 2022, 128.45 in Q2 2022, and 161.72 in Q1 2022.

A high interest coverage ratio indicates that the company is generating significantly more operating income than is required to cover its interest expenses. This suggests that Regeneron Pharmaceuticals, Inc. has a strong ability to meet its interest obligations with its current level of earnings.

While it is unknown how the interest coverage ratio has trended in the recent quarters due to lack of data, the historically high ratios from the previous quarters imply a favorable financial position in terms of managing interest payments. Further monitoring of this ratio in subsequent quarters would provide a more comprehensive understanding of the company's financial health and its ability to withstand interest rate fluctuations.